Significant Developments: HENLIUS (02696) has obtained approval in Japan to conduct an international multi-center Phase 2/3 clinical trial for its drug HLX43, either as a monotherapy or in combination with PIMURUTAMAB HLX07, for the treatment of advanced squamous non-small cell lung cancer. EDDING GENOR (06998) announced that Candid Therapeutics has been acquired by UCB, with an upfront payment of US$2 billion. ISP GLOBAL (08487) is currently in discussions with potential large-scale partners in the food and beverage industry regarding cooperation within mainland China. SWANGCHAICHUAN (02321) has entered into a joint venture agreement with HCT for the financing, development, and operation of a sheep-derived nano-collagen production facility in Collie, Western Australia.
Operating Performance: SSY GROUP (02005) reported a profit attributable to shareholders of approximately HK$171 million for the first quarter, representing a 1.6% increase compared to the same period last year. Budweiser Brewing Company APAC (01876) released its first-quarter results, with a profit attributable to equity holders of US$226 million, down 3.42% year-on-year. XPENG Group-W (09868) delivered 31,011 new vehicles in April, marking a 13% increase from the previous month.
Share Buybacks: Netease Cloud Music (09899) repurchased 127,000 shares on May 4 for HK$14.9995 million. J&T Express-W (01519) bought back 196,800 shares on May 4 at a cost of HK$19.5037 million. AIA Group (01299) repurchased 70,300 shares on May 4 for HK$60.994 million. COSCO SHIPPING Holdings (01919) repurchased 188,400 shares on May 4, spending HK$27.6214 million.
Comments